

From Anecdote to Evidence: Why Measuring What We Deploy Changes Everything

Robert W. Alexander, MD, FICS*

Regenerative Health-Biocellular / Orthobiologics Program (GARM)

***Corresponding author:** Robert W. Alexander, MD, FICS, Regenerative Health-Biocellular / Orthobiologics Program (GARM)

Citation: Alexander RW. From Anecdote to Evidence: Why Measuring What We Deploy Changes Everything. J Stem Cell Res. 7(2):1-06.

Received: May 07, 2026 | **Published:** May 26, 2026

Copyright© 2026 by Alexander RW. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: The field of regenerative medicine has arrived at an inflection point. Clinicians routinely deploy adipose-derived stromal vascular fraction (tSVF and cSVF) and/or platelet-rich plasma concentrates (HD-PRP) with therapeutic intent, yet in the majority of cases neither the dose administered nor the biological quality of that dose is characterized. Without quantified dose, a documented outcome is merely anecdotal.

Objective: This editorial argues that inexpensive, clinic-deployable hemocytometry, paired with an evolving purpose-built centrifuge platform, can close this gap at the point of care — transforming everyday Orthobiologic procedures into reproducible, dose-tracked clinical encounters that collectively build an evidence base not commonly found outside complex randomized trials.

Discussion: Core challenges include a fundamental vocabulary deficit, the absence of minimum characterization standards for cSVF and HD-PRP at the point of care, and the consequent impossibility of establishing dose–response relationships. A practical documentation framework and a proposed minimum viable documentation standard are presented.

Conclusion: Characterizing the biologic deployed is not a research luxury — it is the minimum requirement of responsible clinical practice. The centrifuge that processes the preparation can also be the instrument that initiates the evidence.

Keywords

Stromal vascular fraction; Platelet-rich plasma; Orthobiologics; Dose–response; Hemocytometry; Regenerative medicine; Point-of-care documentation.

Introduction

The vocabulary problem

Regenerative medicine suffers a terminology deficit that undermines both peer communication and patient consent. Terms such as 'stem cells,' 'SVF,' 'PRP,' and 'stromal cells' are used interchangeably and imprecisely in clinical literature, marketing materials, and even regulatory submissions. Before any meaningful dose–response discussion is possible, the field must agree on what it is measuring. (Table 1) presents a proposed standardized vocabulary.

Term	Precise Definition	Common Misuse
tSVF (raw)	Heterogeneous cell-matrix derived via microcannula; includes stromal, endothelial, immune, and progenitor cells.	Confused with pure MSC preparations or used synonymously with cSVF.
cSVF	Cellular stromal vascular fraction — the living fraction of SVF with documented viability, total cell count, and size distribution.	Often assumed without measurement; 'SVF' used when cell count/viability is unknown.
HD-PRP	High-density platelet-rich plasma with documented platelet concentration $\geq 4\times$ individual patient baseline, confirmed by hemocytometry.	Marketing term applied without documented measurement; concentration relative to baseline rarely specified.
Dose	Total viable nucleated cells (or platelets) delivered to the target tissue, with count, size, and viability characterized.	'A syringe of SVF' or 'a tube of spun PRP' — volume without known biological content.
Viability	Percentage of cells with intact membranes, measured by automated counter, flow cytometry, or fluorescent labeling at time of deployment.	Assumed adequate; rarely tested in office settings.
Response	A quantified, pre-specified outcome measure recorded at defined intervals post-treatment.	Patient-reported improvement; VAS scores without documented baseline.

Table 1: Proposed standardized terminology for Orthobiologic dose documentation.

Foundational Principle: A treatment cannot be said to have worked if the treatment itself was never defined. Characterizing the biologic deployed is not a research luxury — it is the minimum requirement of responsible clinical practice.

Standards: What Must Be Measured and Why

cSVF characterization parameters

The International Society for Cell and Gene Therapy (ISCT) and analogous bodies have established minimal criteria for mesenchymal stromal cell (MSC) characterization in research settings — surface marker expression, differentiation capacity, and plastic adherence. These criteria are appropriate for laboratory contexts but remain impractical in same-day small clinical procedures. The clinically actionable minimum for cSVF consists of at least three parameters (Table 2).

Parameter 1	Parameter 2	Parameter 3
Viability	Total Count	Size Profile
% viable nucleated cells at time of injection (target ≥80%)	Absolute nucleated cell number per mL of final preparation	Mean diameter and distribution (μm) — proxy for cell-type composition

Table 2: Minimum three-parameter characterization standard for point-of-care cSVF documentation.

Size matters more than is commonly appreciated. Stromal/progenitor cells in cSVF typically range 10–20 μm as measured by culture expansion. Erythrocyte contamination (6–8 μm) and large adipocyte remnants (often >40–110 μm) may skew counts and alter apparent cell numbers without adding therapeutic nucleated cells. A hemocytometer with trypan blue exclusion provides a useful baseline; automated counters and flow cytometers offer superior discrimination of relevant cell populations within minutes at a reasonable per-test reagent cost. Small countertop units are commercially available at accessible price points.

HD-PRP characterization parameters

The Mishra classification, the Dohan-Ehrenfest framework, and the PAD (Platelet, Activation, Dose) classification each attempt to standardize PRP nomenclature. All agree on one foundational requirement: platelet concentration must be expressed relative to the individual patient's whole-blood baseline.

Example: A preparation achieving 900,000 platelets/μL constitutes HD-PRP in a patient whose baseline is 150,000/μL (6× concentration), but represents only moderate PRP in a patient whose baseline is 300,000/μL (3× concentration). Without a baseline hemocytometric count, the concentration ratio — arguably the single most clinically meaningful number in PRP therapy — is unknowable.

Clinical Implication: Two patients receiving 'PRP' from the same centrifuge protocol on the same day may receive preparations differing by 3–4× in platelet dose. Without baseline measurement, this variability is invisible to the clinician and undetectable in outcome analysis. This concentration differential can and should be related to actual outcomes.

The Centrifuge as a Measurement Platform

The clinical centrifuge has historically functioned as an output device — it produces a preparation, and that preparation is used. The conceptual shift argued for here is that a purpose-configured centrifuge system, when paired with integrated or adjacent hemocytometric analysis, becomes a measurement platform. This reframing has profound consequences for dose documentation.

The platform under discussion is an all-purpose device capable of processing both adipose tissue (for cSVF) and whole blood (for HD-PRP) within the same clinical encounter. This capability is not a convenience — it is scientifically essential. In biocellular/Orthobiologic procedures, tSVF or cSVF and HD-PRP are typically co-deployed. Characterizing one without the other documents only half the dose data in any given application. (Figure 1) illustrates the integrated five-step documentation workflow.

<p>01 Baseline Draw Whole-blood hemocytometry establishes patient-specific platelet baseline before processing begins.</p>	<p>02 Dual Processing Single centrifuge platform processes adipose harvest and blood concurrently using protocol-specific parameters.</p>	<p>03 cSVF Analysis Flow cytometry and hemocytometry: viability %, total count, and size distribution recorded pre-deployment.</p>	<p>04 HD-PRP Analysis Post-spin platelet count expressed as concentration ratio vs. documented individual baseline.</p>	<p>05 Dose Record Complete biological dose characterized and logged before needle enters patient — linked to outcome tracking.</p>
---	--	---	--	---

Figure 1: Integrated point-of-care dose documentation workflow for concurrent cSVF and HD-PRP processing.

This workflow requires no major laboratory infrastructure beyond a small flow cytometer and hemocytometer. The time cost is approximately 8–15 minutes added to the procedure preparation phase. The informational gain is the difference between a characterized biological dose and an uncharacterized biological guess. This approach does not advocate expansion of indications for cSVF; rather, it advocates for documentation of what is actually being delivered to patients undergoing targeted Orthobiologic therapies.

Dose–Response: The Core Scientific Obligation

Every pharmacological and biological therapy approved by regulatory bodies rests on a demonstrated dose–response relationship: as dose increases within a therapeutic range, response changes in a predictable and characterizable way. This relationship is not a regulatory formality. It is the mechanistic signature that distinguishes a therapy from a placebo and an active ingredient from an inert one.

Regenerative cell therapies have, with some notable exceptions, evaded this standard — not because the relationship does not exist, but because dose has not been measured. When every patient receives an unknown dose, dose–response analysis is mathematically impossible regardless of how many patients are enrolled or how carefully outcomes are tracked.

Beyond research and clinical trials: the orthobiologic case

The conventional assumption is that cSVF characterization matters primarily for systemic administration in research protocols or formal clinical trials — intravenous or intrathecal delivery where regulatory scrutiny demands cellular documentation. This assumption deserves direct challenge.

In musculoskeletal and Orthobiologic applications — including tendon/ligament repair, meniscal treatment, intra-articular injection, periosteal delivery, and intramuscular placement — the dose–response question is equally relevant and arguably more tractable. The target tissue is accessible. Outcome measures (VAS pain scores, functional indices, imaging findings) are standardized. The patient population is large and the conditions — osteoarthritis, tendinopathy, ligamentous injury — are among the most prevalent in clinical medicine.

Opportunity Statement: A network of small clinics, each documenting delivered cSVF within the utilized tSVF and HD-PRP at the point of care, and each recording outcomes at standardized intervals, collectively generates a dose-linked outcomes dataset that no single academic medical center could produce in a decade of randomized trials. The unit of evidence production shifts from the trial to each treated encounter.

The potential value extends further. In biocellular/Orthobiologic procedures where concentrations of measured cSVF and HD-PRP are accurately defined and combined, the interaction between the two biologics — whether synergistic, additive, or independent — cannot be assessed unless both doses are characterized. A clinician observing a superior outcome in one patient versus another cannot attribute the difference to preparation technique, processing protocol, or patient biology if the doses administered were never measured.

Transitioning from Anecdote: A Practical Framework

What anecdotal evidence is — and is not

Anecdotal evidence is not without value. The case report and clinical observation have introduced more therapeutic innovations than is commonly credited. The limitation of anecdotal evidence is not its origin but its architecture: it cannot be aggregated, weighted, or falsified. Ten positive case reports and two negative ones cannot be combined into a meaningful signal because the underlying doses, patient characteristics, and outcome definitions are incommensurable.

The transition from anecdote to evidence does not always require a randomized controlled trial. It requires three things: a defined and measured dose, pre-specified outcome measures with a documented baseline, and a record-keeping system that links the two. Each of these is achievable in any clinic that has adopted point-of-care hemocytometry and cSVF documentation.

Minimum viable documentation standard

The following represents a proposed minimum documentation set for any biocellular/Orthobiologic procedure involving cSVF and/or HD-PRP (Table 3).

Data Element	When recorded	Method
Platelet baseline	Day of procedure, pre-processing	Hemocytometry of whole blood
cSVF viability (%)	Post-processing, pre-injection	Manual, automated counting, or flow cytometry
Total nucleated cell count	Post-processing, pre-injection	As above
Mean cell diameter (μm)	Post-processing	Calibrated reticle or automated cell counter
HD-PRP concentration ratio	Post-spin, pre-injection	Post-spin platelet count \div documented baseline
Volume deployed	At injection	Syringe measurement
Outcome measure (baseline)	Day of procedure	VAS, KOOS, DASH, or condition-appropriate PRO
Outcome measure (follow-up)	8, 12, 24, and 52 weeks	Standardized PRO linked to documented dose record

Table 3: Proposed minimum documentation standard for biocellular/Orthobiologic procedures.

Implications for the Field

The argument presented here is not that small clinics should become research centers. It is that the act of measuring what you deploy — an act that requires minutes and costs relatively little — transforms a clinical procedure into a data-generating encounter. Aggregated across hundreds of practitioners treating thousands of patients, dose-linked outcome records constitute a form of evidence that is complementary to, and not simply inferior to, randomized trial data.

The evolving all-purpose centrifuge platform capable of processing both cSVF and HD-PRP, paired with affordable hemocytometry and cell counting, provides the basic technical infrastructure for this transition. What then remains is the adoption of a shared vocabulary, a commitment to minimum documentation standards, and the recognition that the dose–response relationship is not a research question to be answered someday — it is a clinical question being generated every time a syringe is loaded without measuring its contents.

Summary principle: Characterizing cSVF is not a burden reserved for clinical trials involving systemic delivery. It is a core obligation of any practitioner who wishes to understand why their patients improve, why some improve more than others, and how to reproduce success. The centrifuge that processes the preparation can also be the instrument that initiates the evidence.

Disclosure statement

This editorial is prepared for educational and professional discussion purposes. It does not constitute regulatory guidance or clinical practice endorsement. All referenced measurement parameters should be implemented within applicable regulatory frameworks governing autologous cell preparation and deployment in the practitioner's jurisdiction. The author reports no conflicts of interest directly relevant to the subject matter of this editorial.

References